Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

被引：6
|
作者：
Shah, Jatin J. [1 ]
Feng, Lei [2 ]
Thomas, Sheeba K. [3 ]
Weber, Donna [3 ]
Wang, Michael [4 ]
Manasanch, Elisabet E. [3 ]
Mendoza, Kathleen [3 ]
Orlowski, Robert Z. [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.1540.1540
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Vesole, David H.
    Bilotti, Elizabeth
    Richter, Joshua R.
    McNeill, Ann
    McBride, Laura
    Raucci, Laura
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    Smith, Judith
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Mato, Anthony
    Siegel, David S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 52 - 59
  • [42] A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mikhael, J.
    Richardson, P.
    Usmani, S.
    Raje, N.
    Bensinger, W.
    Kanagavel, D.
    Gao, L.
    Ziti-ljajic, S.
    Anderson, K.
    HAEMATOLOGICA, 2017, 102 : 168 - 168
  • [43] Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro-prospective observational study
    Del Giudice, Maria Livia
    Gozzetti, Alessandro
    Antonioli, Elisabetta
    Attucci, Irene
    Pengue, Ludovica
    Cassano Cassano, Raffaella
    Ghio, Francesco
    Orciuolo, Enrico
    Simoncelli, Martina
    Bocchia, Monica
    Galimberti, Sara
    Buda, Gabriele
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (04) : 373 - 380
  • [44] Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
    Dubey, A. P.
    Khatri, Sameer
    Maggo, Sachin
    Singh, Nilabh K.
    Sharma, Durgesh
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (06) : 846 - 849
  • [45] Selinexor for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Anum, Babar
    Hina, Zubair
    Mainoma, Bano
    Sana, Rafique
    Arzu, Shahid
    Maham, Babar
    Waleed, Madeeha S.
    Arslan, Inayat
    Danish, Safi
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S29 - S29
  • [46] Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
    Jayaweera, Shansa Pranami E.
    Wanigasinghe Kanakanamge, Sacheela Prasadi
    Rajalingam, Dharshika
    Silva, Gayathri N.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [47] Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
    Chari, Ajai
    Larson, Sarah
    Holkova, Beata
    Cornell, Robert F.
    Gasparetto, Cristina
    Karanes, Chatchada
    Matous, Jeffrey V.
    Niesvizky, Ruben
    Valent, Jason
    Lunning, Matthew
    Usmani, Saad Z.
    Anderson, Larry D., Jr.
    Chang, Lipo
    Lee, Yihua
    Pak, Yvonne
    Salman, Zeena
    Graef, Thorsten
    Bilotti, Elizabeth
    Chhabra, Saurabh
    LEUKEMIA & LYMPHOMA, 2018, 59 (11) : 2588 - 2594
  • [48] ANCHOR (OP-104) Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI): Phase 1 Update
    Pour, Ludek
    Efebera, Yvonne A.
    Granell, Miquel
    Hajek, Roman
    Oriol, Albert
    Delaunay, Jacques
    Le Du, Katell
    Eveillard, Jean-Richard
    Karlin, Lionel
    Maisnar, Vladimir
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Norkin, Maxim
    Ribrag, Vincent
    Richardson, Paul G.
    Straub, Jan
    Byrne, Catriona
    Jacques, Christian
    Sydvander, Malin
    Ocio, Enrique
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S326 - S327
  • [49] Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Alegria, Victoria R.
    Ahmed, Salman
    Laplant, Betsy
    Manna, Alak
    Parrondo, Ricardo
    Roy, Vivek
    Sher, Taimur
    Edwards, Brett
    Lanier, Stephanie
    Jackson, Keisha
    Chanan-Khan, Asher A.
    Paulus, Aneel
    BLOOD, 2019, 134
  • [50] Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): frailty subgroup analysis from phase 3 ASPIRE and ENDEAVOR
    Facon, Thierry
    Niesvizky, Ruben
    Weisel, Katja
    Bringhen, Sara
    Ho, P. Joy
    Obreja, Mihaela
    Yang, Zhao
    Klippel, Zandra
    Blaedel, Julie
    Mezzi, Khalid
    Siegel, David S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E266 - E266
12345